Patents Examined by Paul V. Ward
  • Patent number: 11414413
    Abstract: Disclosed are a heterocyclic derivative as a JAK inhibitor, and salts thereof, wherein the definitions of (II), (III) and R are described in detail in the specification. In addition, also disclosed are a medicine including the compound and salts thereof as an active ingredient, and the use thereof in the preparation of a medicine for treating JAK-related target diseases, such as immune system diseases, rheumatoid arthritis and tumors.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 16, 2022
    Assignee: Suzhou Longbiotech Pharmaceuticals Co., Ltd.
    Inventors: Hengying Yang, Sheng Kuang, Shiwei Li, Kuiwang Wu, Shuxin Li
  • Patent number: 11414385
    Abstract: Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: August 16, 2022
    Inventors: Rima McLeod, Martin McPhillie, Colin W. G. Fishwick, Hernan Alejandro Lorenzi, Kai Wang, Taek-Kyun Kim, Yong Zhou, Leroy E. Hood, Ying Zhou, Kamal El Bissati, Mark Hickman, QiGui Li, Craig Roberts
  • Patent number: 11414411
    Abstract: The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), or a salt thereof, or a solvate including hydrate thereof, and/or intermediates thereof, and the use of intermediates for preparing Compound X. In particular, the process relates to the preparation of Compound X using dynamic kinetic resolution (DKR) and asymmetric catalytic reduction, thereby providing an improved route to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (Compound X) and compositions containing said compound, including the arginine salt, sodium salt and hydrated solid forms of Compound X.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: August 16, 2022
    Assignee: Novartis AG
    Inventors: Like Chen, Chi Ming Cheung, Zhongbo Fei, Qun Jiang, Lei Li, Bin Li, Thomas Ruch, Hao Wang, Quanbing Wu
  • Patent number: 11414400
    Abstract: The present invention relates to a method for preparing sulfonamides which are inhibitors of Bcl-2/Bcl-xL, comprising the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoro methylsulfonyl-anilino)-4-phenylthio-butyl)-4-hydroxyl-piperidine, and the present invention also relates to intermediates for the preparation of the sulfonamides, a new final product and its therapeutic use, and pharmaceutical use.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: August 16, 2022
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Ming Guo, Jianfeng Wen, Tianzhu Wu, Huirong Lu, Feng Xu
  • Patent number: 11407735
    Abstract: The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5 -yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: August 9, 2022
    Assignee: NOVARTIS AG
    Inventors: Stephanie Kay Dodd, Arnaud Grandeury, Emmanuel Suffert, Evgenia Rousaki
  • Patent number: 11407733
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 9, 2022
    Assignees: Bristol-Myers Squibb Company
    Inventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
  • Patent number: 11406621
    Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided containing the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a disaccharide species.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 9, 2022
    Assignee: KOWA COMPANY, LTD.
    Inventors: Shin Sugimoto, Akito Minamizono
  • Patent number: 11406640
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: August 9, 2022
    Assignee: Incyte Corporation
    Inventors: Richard L. Schaub, Kevin O'Hayer
  • Patent number: 11401280
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: August 2, 2022
    Assignees: Incyte Holdings Corporation, Incyte Corportion
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Patent number: 11400088
    Abstract: The present invention provides uses of a compound represented by formula A in the preparation of drugs for treating brain glioma and particularly glioblastoma. Particularly provided are uses of the compound represented by formula A in the preparation of drugs for treating expression of specific fusion protein. By means of the technical solution of the present invention, typing of brain glioblastoma can be implemented, a drug administration can be carried out for a specific patient group, and precise treatment can be implemented.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 2, 2022
    Assignees: BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY, BEIJING NEUROSURGICAL INSTITUTE
    Inventors: Tao Jiang, Yanwei Liu, Huimin Hu, Hepeng Shi, Weizhe Xue
  • Patent number: 11401231
    Abstract: This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 2, 2022
    Assignee: OZCHELA INC.
    Inventors: Min-Kyung Lee, Jin-Kak Lee, Won-Seok Han
  • Patent number: 11390622
    Abstract: The present invention provides pyrimidine-isoquinolin-quinone derivatives of formula I, their salts, isomers, pharmaceutically acceptable tautomers; pharmaceutical composition; preparation procedure; and their use in the treatment of bacterial and resistant bacterial diseases, such as methicillin-resistant Staphylococcus aureus (MRSA), intermediate vancomycin-resistant Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus spp. (VRE), Enterococcus faecalis, Emerging Staphylococcus aureus with resistance to linezolid and/or bacterial strains not susceptible to daptomycin. Where the radicals R1, R2, R3, R4 and R5 are as defined in the work specifications of the present invention.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 19, 2022
    Assignee: UNIVERSIDAD DE CHILE
    Inventors: David Reinaldo Vásquez Velásquez, Juan Andrés Andrades Lagos, Javier Andrés Campanini Salinas
  • Patent number: 11384100
    Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 12, 2022
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Anvarhusein A. Isab, Adam Ahmed Abdullah Sulaiman
  • Patent number: 11384086
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: July 12, 2022
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Patent number: 11382875
    Abstract: Methods of modulating the interaction between ?-amyloid and ?7-nAChR are provided. Aspects of the methods include administering to the subject an effective amount of a naphthalene derivative active agent. Compositions and kits for practicing the subject methods are also provided. The methods, compositions and kits find use in treating a variety of applications, such as treating a subject for a neurodegenerative disease, e.g., Alzheimer's disease.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: July 12, 2022
    Assignees: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Collaborations Pharmaceuticals, Inc.
    Inventors: Aaron McMurtray, Julia Chung, Natalie Diaz, Sean Ekins
  • Patent number: 11376247
    Abstract: Methods for inducing the regeneration of non-cancerous tissues in a cancer patient undergoing radiotherapy and/or chemotherapy using continuous administration of tyrosine kinase inhibitors for at least 90 days following a cancer treatment in the patient.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: July 5, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Mary Reyland, Sten Wie
  • Patent number: 11377452
    Abstract: The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: July 5, 2022
    Assignee: Drexel University
    Inventors: Sandhya Kortagere, Andreia C. K. Mortensen, Ole V. Mortensen, Joseph M. Salvino
  • Patent number: 11370779
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used, it can effectively inhibit the activity of FLT3 kinase and can be usefully used to prevent or treat acute myeloid leukemia or metastatic breast cancer.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: June 28, 2022
    Assignee: PELEMED CO., LTD.
    Inventors: Yong Chui Kim, Pyeong-Hwa Jeong
  • Patent number: 11370792
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 28, 2022
    Assignee: Raze Therapeutics, Inc.
    Inventors: Nello Mainolfi, Mikel P. Moyer, Eddine Saiah, Cristina Lecci, Robert David Matthew Pace, Heather Tye, Julia Vile
  • Patent number: 11370771
    Abstract: The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R4, R7 to R10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: June 28, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Angela Kay Berry, Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Matthew Russell Netherton